drugset
drugset / Trial / NCT03657446

A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

NCT03657446 ↗

Phase 1 Completed 36 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverTriple-blindOther

Summary

The study will investigate whether administration of clazosentan can affect normal heart function in healthy subjects

Timeline

Start
2018-09-18
Primary completion
2018-10-26
Completion
2018-10-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clazosentan Small molecule 20 mg Intravenous
Subject Clazosentan Small molecule 60 mg Intravenous
Subject Moxifloxacin Small molecule 400 mg —

Indications

No indication recorded.